CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Ning Zhao(University of California, San Francisco), Michael J. Evans(University of California, San Francisco)
Cited by 30
Related Papers
Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling
|Molecular & Cellular Proteomics|2019|14
Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
|Clinical Cancer Research|2023|11
674 Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving ¹ <sup>7</sup> <sup>7</sup> Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response
|Regular and Young Investigator Award Abstracts|2025|0